TABLE 2.

Risk Factors for Incident DM Among Participants With No Prior Statin Exposure, the HOPS, 2002–2011 (N = 4692)

Variable	Univariate Analysis		Multivariable Analysis		Multivariable Analysis with Propensity Score Adjustment
	Hazard Ratio	P	Hazard Ratio	P	Hazard Ratio	P
Statin exposure (per 1 yr)*	1.19 (1.07–1.32)	0.002	1.14 (1.02–1.28)	0.020	1.14 (1.02–1.27)	0.019
Age (per 10 yrs)	1.52 (1.37–1.69)	<0.001	1.59 (1.42–1.77)	<0.001	1.94 (1.32–2.86)	<0.001
Sex
Female	1.51 (1.20–1.90)	<0.001	1.13 (0.89–1.45)	0.320	1.14 (0.89–1.45)	0.320
Male	Referent		Referent		Referent
Race/ethnicity
Hispanic/Latino	2.21 (1.64–2.98)	<0.001	1.96 (1.44–2.66)	<0.001	1.86 (1.35–2.57)	<0.001
Non-Hispanic/Latino black	1.69 (1.33–2.14)	<0.001	1.39 (1.08–1.79)	0.012	1.17 (0.79–1.75)	0.435
Non-Hispanic/Latino white	Referent		Referent		Referent
Antiretroviral history
Naive	1.16 (0.92–1.47)	0.206	1.34 (1.05–1.70)	0.019	1.23 (0.93–1.64)	0.153
Experienced	Referent		Referent		Referent
Prevalent hepatitis C	1.96 (1.53–2.51)	<0.001	1.60 (1.24–2.06)	0.003	1.55 (1.20–2.01)	<0.001
BMI, kg/m2
<25	Referent		Referent		Referent
25–29	1.19 (0.91–1.55)	0.198	1.18 (0.90–1.54)	0.229	1.26 (0.94–1.70)	0.122
≥30	3.19 (2.57–4.12)	<0.001	2.95 (2.26–3.84)	<0.001	3.58 (2.30–5.59)	<0.001
PI use (per 1 yr)*	1.59 (0.85–2.96)	0.144	1.74 (0.93–3.25)	0.085	1.73 (0.92–3.24)	0.087
Propensity score†					0.051 (0.00–11.43)	0.282

^*Cumulative use during study period.

^†See Methods for description.